Spinal Muscular Atrophy Market
May 06, 2019
SMA (Spinal Muscular Atrophy) – a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing.
Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). Need more information on SMA market.
Downloads
Article in PDF
Recent Articles
- Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives
- Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA
- FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulce...
- Can Spinal Muscular Atrophy be treated by Protease Inhibitors?
- Meet the World’s most expensive drug: Zolgensma
Downloads
Article in PDF
Recent Articles
- FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulce...
- Novartis’ Canakinumab for NSCLC; Novartis’s Zolgensma Updates; Trodelvy Prospects in New Breast C...
- Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA
- Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s ...
- Spinal Muscular Atrophy Emerging therapies
